335
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Comparative effectiveness: beyond the buzz

Pages 1036-1038 | Published online: 19 Nov 2012

References

  • NIHCM. Changing patterns of pharmaceutical innovation. A research report by The National Institute for Health Care Management Research and Educational Foundation. NIHCM, 2002.
  • Garattini L, et al. Pricing and reimbursement of in-patent drugs in seven European countries: a comparative analysis. Health Policy 2007.
  • INAHTA. http://www.inahta.org/HTA/. Accessed November 2012.
  • High Level Pharmaceutical Forum. http://ec.europa.eu/pharmaforum/ Accessed November 2012.
  • AHRQ 2007. Methods reference guide for effectiveness and comparative effectiveness reviews agency for healthcare research and quality. Methods reference guide for effectiveness and comparative effectiveness reviews, Version 1.0 [Draft posted Oct. 2007]. Rockville, MD: Available at: http://effectivehealthcare.ahrq.gov/repFiles/2007_10DraftMethodsGuide.pdf. Accessed November 2012.
  • Senate of the USA. Amendment 2786. Comparative Effectiveness Research, 2009
  • Weinstein MC, Skinner J. Comparative effectiveness and health care spending — Implications for reform. N Engl J Med 2010;362:5
  • Drummond MF, Schwartz JS, Jönsson B, et al. Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care 2008;24:244–58
  • Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 2011;14:417–28
  • Wolowacz et al. 2008.
  • Carlson JJ, Sullivan SD, Garrison LP, et al. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy 2010;96:179–90
  • Annemans L, Cleemput I, Hulstaert F, et al. Valorising and creating access to innovative medicines in the European union. Front Pharmacol 2011;2:5.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.